Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia

Inclusion Criteria: Male or female between 18 and 85 years of age inclusive, at the time of signing the informed consent. Patients with post-herpetic neuralgia (PHN) with pain at screening present for more than 3 months after healing of the herpes zoster skin rash. The maximum duration of PHN will be no longer than 5 years. Exclusion Criteria: Patients having other severe pain, which may impair the self-assessment of the pain due to PHN. Patients who have received nerve blocks for neuropathic pain within 4 weeks prior to the start of the single-blind placebo run-in Certain medications used to relieve the pain of PHN, specifically gabapentinoids (gabapentin and pregabalin), carbamazepine and topical agents (eg capsaicin, lidocaine) Patients with a documented failure to respond to a maximally tolerated dose regimen of gabapentin or pregabalin. Patients taking more than one medication to treat the PHN pain